172 related articles for article (PubMed ID: 21197273)
1. Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.
Sadeghi B; Al-Hashmi S; Hassan Z; Rozell B; Concha H; Lundmark C; Grönvik KO; Abedi-Valugerdi M; Hassan M
Clin Dev Immunol; 2010; 2010():142943. PubMed ID: 21197273
[TBL] [Abstract][Full Text] [Related]
2. Migration and activation of T cells during development of graft-versus-host disease in a mouse model.
Wen HS; Wang JM; Zhou H; Gong SI; Gao L; Wu Y
Transplant Proc; 2013 Mar; 45(2):713-8. PubMed ID: 23498811
[TBL] [Abstract][Full Text] [Related]
3. GVHD after chemotherapy conditioning in allogeneic transplanted mice.
Sadeghi B; Aghdami N; Hassan Z; Forouzanfar M; Rozell B; Abedi-Valugerdi M; Hassan M
Bone Marrow Transplant; 2008 Dec; 42(12):807-18. PubMed ID: 18820712
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.
Al-Hashmi S; Hassan Z; Sadeghi B; Rozell B; Hassan M
Int J Clin Exp Pathol; 2011 Aug; 4(6):596-605. PubMed ID: 21904635
[TBL] [Abstract][Full Text] [Related]
5. Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice.
Mochizuki K; Xie F; He S; Tong Q; Liu Y; Mochizuki I; Guo Y; Kato K; Yagita H; Mineishi S; Zhang Y
J Immunol; 2013 Apr; 190(7):3772-82. PubMed ID: 23440416
[TBL] [Abstract][Full Text] [Related]
6. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
Wang J; Li L; Xu M; Rong R; Zhu T
Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
[TBL] [Abstract][Full Text] [Related]
7. Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.
He X; Ye Y; Xu X; Wang J; Huang Y; Weng G; Zhang M; Guo K
Biomed Res Int; 2016; 2016():3071214. PubMed ID: 27843940
[TBL] [Abstract][Full Text] [Related]
8. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.
Ross D; Jones M; Komanduri K; Levy RB
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1430-8. PubMed ID: 23819914
[TBL] [Abstract][Full Text] [Related]
9. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
10. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
[TBL] [Abstract][Full Text] [Related]
11. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
[TBL] [Abstract][Full Text] [Related]
12. Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
Shahin K; Mattar Z; Silveira P; Hsu WH; Bendall L; Hart D; Bradstock KF
Transplantation; 2017 Nov; 101(11):2695-2704. PubMed ID: 28319565
[TBL] [Abstract][Full Text] [Related]
13. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
[TBL] [Abstract][Full Text] [Related]
14. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
[TBL] [Abstract][Full Text] [Related]
15. Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function.
Leigh ND; O'Neill RE; Du W; Chen C; Qiu J; Ashwell JD; McCarthy PL; Chen GL; Cao X
J Immunol; 2017 Jul; 199(1):336-347. PubMed ID: 28550198
[TBL] [Abstract][Full Text] [Related]
16. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice.
Xun CQ; Thompson JS; Jennings CD; Brown SA; Widmer MB
Blood; 1994 Apr; 83(8):2360-7. PubMed ID: 8161803
[TBL] [Abstract][Full Text] [Related]
17. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.
Yang YG; Qi J; Wang MG; Sykes M
Blood; 2002 Jun; 99(11):4207-15. PubMed ID: 12010827
[TBL] [Abstract][Full Text] [Related]
18. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
19. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
[TBL] [Abstract][Full Text] [Related]
20. Host-derived CD8⁺ dendritic cells protect against acute graft-versus-host disease after experimental allogeneic bone marrow transplantation.
Weber M; Rudolph B; Stein P; Yogev N; Bosmann M; Schild H; Radsak MP
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1696-704. PubMed ID: 25132527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
